Lupin Manufacturing Solutions has been gaining visibility lately. For those who might not be familiar, how would you describe LMS and its vision within the Lupin Group?

 Lupin Manufacturing Solutions (LMS) represents Lupin’s commitment to extending its scientific excellence and manufacturing quality into the CDMO space. LMS was created with a clear vision to collaborate with innovators, biotech firms, and pharmaceutical companies to accelerate their molecules from development to commercial scale, with the assurance of Lupin’s global quality and compliance standards.

In essence, LMS blends Lupin’s heritage of trust with the flexibility and customer-focus of a pure-play CDMO. That’s our DNA.

What makes LMS different in an increasingly competitive global CDMO market?

The CDMO industry today is not about who has the largest capacity, rather it’s more about who brings the most value, scientific innovation and speed to the table. Our edge lies in complex chemistry capabilities, deep regulatory expertise, and a culture built around collaboration and accountability.

We focus on areas where precision and containment matter including highly potent APIs, oncology, and niche small molecules, and we back that with teams who think beyond manufacturing, toward solving our clients’ development and commercialization challenges.

Dr. Abdelaziz, you mentioned oncology as a key focus area. Can you share more about LMS’s plans in this space?

Yes, and I am happy to share this first with PharmaCompass that we have just commissioned our new Oncology block at our Vizag site, which is now operationally ready.

This is a major step forward for LMS. The facility has been purpose-built for high-potency and oncology APIs, equipped with advanced containment systems, over 20 reactors and 20+ isolators, and staffed by a team of 100+ highly skilled scientists specializing in complex and hazardous chemistries.

It expands both our capacity and our confidence to support partners developing targeted cancer therapies. More importantly, it signals our intent that we are serious about being a global partner of choice in the oncology CDMO space.

That is an exciting development. What opportunities do you see in the Oncology manufacturing segment globally?

 The oncology segment is transforming the pharmaceutical landscape and infact one of the segments with highest number of development drugs in pipeline globally. With the rise of targeted therapies, potent compounds, and smaller-volume high-value APIs, clients are looking for CDMO partners who combine containment expertise with speed and reliability.

We see a strong opportunity here, especially as innovators look to move from lab to commercial scale faster, without compromising safety or compliance. LMS is stepping into that gap with the right infrastructure, people, and mindset to deliver.

As CPHI Frankfurt is around the corner, what can we expect from LMS this year?

This CPHI will be a defining one for us. We will be showcasing LMS as a comprehensive small-molecule CDMO, with a sharpened focus on high-potency and oncology manufacturing.

Our conversations in Frankfurt will center on how we can help clients navigate development complexity with the confidence of partnering with a science-first, quality-driven CDMO. People will see a refreshed LMS – one that’s growing fast, innovating continuously, and thinking globally.

Quality and sustainability are gaining importance in CDMO partnerships. How is LMS addressing these dimensions?

For us, quality and sustainability are a part of our culture. Every process at LMS is anchored in patient safety, compliance, and continuous improvement. Our regulatory systems are built on decades of Lupin’s global experience, and we are leveraging that legacy in every project we take on.

On sustainability, we are investing in green chemistry principles, waste minimization, and energy-efficient operations. We believe responsible manufacturing is not just an ESG statement; it’s good business and essential for long-term trust.

Partnership seems to be a recurring theme for LMS. How do you define a true CDMO partnership?

 A real partnership starts with shared ambition. We see ourselves not just as a manufacturer, rather an innovation partner working as an extension of our client’s R&D and operations teams. The most successful projects we have delivered are those where we have been involved early, aligning on development strategy, risk management, and commercial readiness.

That is what we mean when we say we are building science-led partnerships – partnerships that are collaborative, transparent, and outcome-driven.

Finally, what is next for LMS as you look beyond this milestone?

The Oncology block is just the beginning of a larger journey. We are scaling our analytical and development services, peptide synthesis capabilities, adding bioconjugation services, expanding global business development, and investing in digital and automation initiatives to make project execution even more seamless. Our goal is to evolve into a trusted global CDMO partner that combines Lupin’s credibility with next-generation manufacturing and scientific agility.

As I like to say – we are not just manufacturing APIs; we are manufacturing trust, innovation, and long-term partnerships.

This interview was first published in the Pharma Compass on Oct 22, 2025